Gastrointestinal Cancer and Neuroendocrine Tumors
| Study | Design | Patients (n) | PET/MRI | Cancer type | Indication | T-staging | N-staging | M-staging | Superiority |
| Lee (44) | Prospective | 15 | Sequential | Esophageal | Staging | — | NS | — | ND |
| Paspulati (47) | Prospective | 12 | Sequential | Colorectal | Staging, restaging | — | — | — | ND (no enhanced CT) |
| Brendle (48) | Retrospective | 15 | Simultaneous | Colorectal | Staging, restaging | — | NS | NS | ND |
| Reiner (49) | Prospective | 55 | Sequential | Liver lesions | Staging, restaging | — | — | — | ND |
| Beiderwellen (50) | Prospective | 70 | Simultaneous | Liver lesions | Staging, restaging | — | — | — | ND |
| Gaertner (76) | Prospective | 24 | Simultaneous | NET | Staging, restaging | — | — | — | ND |
| Hope (77) | Prospective | 10 | Simultaneous | NET | Staging, restaging | — | — | — | MRI superior for liver lesions; no validation |
| Total | 201 |
NS = nonsignificant; ND = no difference; — = not reported.